Narrative Review: Tantangan dan Strategi Pemanfaatan Big Data dalam Farmakovigilans di Indonesia

Authors

  • Aulia Syafadilla Azali Universitas Ahmad Dahlan
  • Miftakhul Yusron Universitas Ahmad Dahlan
  • Endang Darmawan

DOI:

https://doi.org/10.30595/pharmacy.v22i1.26614

Keywords:

Big Data, Efek Samping Obat, Farmakovigilans, Kecerdasan Buatan, Machine Learning

Abstract

Farmakovigilans merupakan bidang penting dalam ilmu farmasi dan kesehatan masyarakat yang berperan dalam mendeteksi, menilai, memahami, dan mencegah efek samping obat guna memastikan keselamatan pasien. Seiring perkembangan teknologi informasi, Big data hadir sebagai solusi inovatif yang dapat meningkatkan efektivitas sistem farmakovigilans dengan memanfaatkan data berskala besar dan beragam, seperti rekam medis elektronik, laporan efek samping dari pasien, media sosial, hingga data klaim asuransi. Artikel ini disusun sebagai narrative review yang bertujuan mengeksplorasi tantangan dan strategi dalam pemanfaatan Big data pada farmakovigilans. Metode yang digunakan adalah penelusuran literatur dari database ilmiah internasional seperti PubMed, ScienceDirect, SpringerLink, dan lainnya, dengan kriteria inklusi artikel relevan yang diterbitkan antara tahun 2015–2025. Hasil kajian menunjukkan bahwa pemanfaatan Big data menghadapi berbagai tantangan seperti heterogenitas data, keterbatasan interoperabilitas sistem, masalah etika dan privasi, variasi kualitas data, hingga belum adanya standar regulasi global. Meski demikian, sejumlah strategi telah dikembangkan untuk mengatasi tantangan tersebut, antara lain dengan menerapkan kecerdasan buatan dan machine learning, membangun infrastruktur data yang terintegrasi, serta memperkuat kolaborasi antar pemangku kepentingan. Selain itu, analisis prediktif dan deteksi dini efek samping semakin dimungkinkan melalui integrasi teknologi dan pendekatan berbasis data nyata. Kesimpulan dari kajian ini menegaskan bahwa Big data berpotensi merevolusi sistem farmakovigilans, namun keberhasilan implementasinya sangat bergantung pada kesiapan regulasi, teknologi, sumber daya manusia, serta etika penggunaan data. Oleh karena itu, dibutuhkan upaya kolaboratif lintas sektor untuk mewujudkan sistem pengawasan obat yang lebih responsif, efisien, dan adaptif terhadap tantangan zaman.

References

Al Zaabi M, Alhashmi SM. 2024. Big data security and privacy in healthcare: A systematic review and future research directions, Information Development, 40(1), 1-15.

Albert N. 2023. Pharmacovigilance in the era of big data: Challenges and opportunities, Journal of Pharmacovigilance, 11(3).

Antunes R S, da Costa CA, Küderle A, Yar, IA, Eskofier B. 2022. Federated learning for healthcare: Systematic review and architecture proposal ACM Transactions on Intelligent Systems and Technology (TIST), 13(4), 1–23.

Baethge C, Goldbeck-Wood S, 2019. SANRA for the quality assessment of narrative review articles, Research Integrity and Peer Review, 4(5).

Bate A, Evans SJW, Hughes B. 2016. Real-world data and decision-making in pharmacovigilance, Drug Safety, 39(10), 935–945.

Dhengale MD, Bathe HN, Nagrik SM. 2025. The role of big data analytics in improving pharmacovigilance: advances, challenges, and future directions, International Journal of Multidisciplinary Engineering In Current Research, 10(2).

Dimitsaki S, Natsiavas P, Jaulent MC. 2024. Applying AI to structured real-world data for pharmacovigilance purposes: Scoping review, Journal of Medical Internet Research, 26, e57824.

Edwards IR. 2017. A new review report considering the safety of medicines in the 21st century, Drug Safety, 40(10), 845–850.

Harpaz R, DuMouchel W, Shah NH, Madigan D, Friedman C. 2014. Novel data-mining methodologies for adverse drug event discovery and analysis, Clinical Pharmacology & Therapeutics, 91(6), 1010–1021

Hussain R, Hassali MA. 2021. Big data, medicines safety & pharmacovigilance, Journal of Pharmaceutical Policy and Practice, 14(1).

Jayathissa P, Hewapathirana R. 2023. Enhancing interoperability among health information systems in low- and middle-income countries: A review of challenges and strategies, arXiv, 2309.12326.

Kiguba R, Olsson SJ, Waitt CJ. 2022. Pharmacovigilance in low‐ and middle‐income countries: A review with particular focus on Africa, British Journal of Clinical Pharmacology, 89(2), 453–464.

Prieto-Merino D, Quartey G, Wang J, Kim J. 2011. Why a Bayesian approach to safety analysis in pharmacovigilance is important, Pharmaceutical Statistics, 10(6), 554–559.

Salas-Vega S, Haimann A, Mossialos E. 2015. Big data and Health Care: challenges and opportunities for coordinated policy development in the EU, Health Systems & Reform, 1(4), 285–300.

Salvo F, Fourrier-Réglat A. 2020. Harnessing big data for pharmacovigilance, Drug Safety, 43(9), 885–893.

Sarker A, Ginn R, Nikfarjam A, O’Connor K, Jayaraman S. Upadhaya T, Gonzalez G. 2015. Utilising social media data for pharmacovigilance: A review, Journal of Biomedical Informatics, 54, 202–212.

Shamim MA, Aroro P, Dwivwedi. 2024. Artificial Intelligence and Big data for pharmacovigilance and patient safety, Journal of Medicine, Surgery, and Public Health.

Siddique MI. 2025. Pharmacovigilance in the era of digital health: Leveraging big data and artificial intelligence for enhanced drug safety monitoring. Asian Journal of Pharmaceutics, 19(01).

Ventola CL. 2018. Big data and pharmacovigilance: Adverse drug events and interactions. Pharmacy and Therapeutics, 43(6):340-351.

Wang SV, Pinheiro S, Hua W, Arlett P, Uyama Y, Berlin JA, & Schneeweiss S. 2019. Big data for pharmacovigilance: An overview of the opportunities and challenges. Clinical Pharmacology & Therapeutics, 106(1), 36–39

Wong A, Plasek JM, Montecalvo SP, Zhou L. 2018. Natural language processing and its implications for the future of medication safety: A narrative review of recent advances and challenges. Pharmacotherapy, 38(8), 822-841.

Zhou X, Menche J, Barabási AL., Sharma A. 2019. Big data hurdles in precision medicine and precision public health. Frontiers in Medicine, 6, 81.

Downloads

Published

2025-08-19

How to Cite

Azali, A. S., Miftakhul Yusron, & Endang Darmawan. (2025). Narrative Review: Tantangan dan Strategi Pemanfaatan Big Data dalam Farmakovigilans di Indonesia. PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia), 22(1), 50–54. https://doi.org/10.30595/pharmacy.v22i1.26614

Similar Articles

> >> 

You may also start an advanced similarity search for this article.